



ASX release

9 March 2016

Patent granted in USA

AtCor Medical (ASX: ACG), AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which noninvasively measures the central arterial pressure waveform, central aortic blood pressures and arterial stiffness indices, today announced that it has received notice of allowance from the United States Patent and Trademark office of a new patent "Brachial Cuff" in USA. This patent closely resembles the patent awarded in Japan announced in February and further confirms AtCor's position as the leader in this field. The patent is in force until May 2031.

"We are delighted to confirm intellectual property protection for our industry leading technology in the world's two largest medical device markets," said AtCor Medical CEO Duncan Ross. "This patent strengthens our market position as we continue rollout of SphygmoCor to doctors in the US\$800 million clinical practice market."

AtCor has begun a sales campaign initially targeting four key metropolitan areas in the US. This follows commencement of the Category 1 CPT Code on 1 January 2016 which allows doctors to bill payers for the SphygmoCor test. Payers include government organisations such as Medicare and Medicaid, and private payer organisations.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements.

More than 4,000 SphygmoCor[®] systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811
p.manley@atcormedical.com

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m.0407 231 282 or
a.rambukwella@fcr.com.au